TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02931357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid 0.54%
Description: Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calgel®
Description: Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
Study: NCT01832753

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levothyroxine
Study: NCT01000233

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phytine (phytate)
Description: 300 mg tid \* 24 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Phytine (Phytate)
Study: NCT01938040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen
Description: single preoperative dose prior to surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sugar water/placebo
Description: single preoperative dose prior to surgery
Study: NCT02566694

Intervention type: PROCEDURE
Intervention: Implant
Description: orthopaedic implant

Intervention type: PROCEDURE
Intervention: Implant
Description: orthopaedic implant
Study: NCT03064919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Curriculum Testing
Description: An evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals was developed by refining an existing curriculum. State-of-the art theories in early childhood science education, innovative virtual technology to provide more realistic simulations of hunger and fullness, and a parent training component to improve long-range sustainability were incorporated. This 9-wk intervention will be tested by forty children (ages 4-5). Key outcomes will be children's adjustment in intake in response to a first course (energy compensation) and children's intake of tasty snacks when not hungry (eating in the absence of hunger). Additionally, the investigators will measure other variables likely to impact the success of the curriculum, for example: child gender/age, parent feeding practices, parent education, infant feeding practices, child/parent weight status, and others.
Study: NCT01526395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The major intervention proposed in this study is the introduction of low dose IV propofol for sedation prior to ECT treatment at C.S.M Medical University. The investigators will use a dose of 0.25 to 0.50 mg/kg of IV propofol. The maximum dose of 0.50 mg/kg is not sufficient for anesthesia (i.e., to make unconscious), but should provide a light level of sedation and be amnestic, meaning the patient should have memory loss for the period of time around the ECT procedure itself. The propofol dose will be titrated upwards (from an initial dose of 0.25 mg/kg) with successive treatments in increments of 0.05mg/kg, until it is just sufficient to be lightly sedating. ECT will be administered 30 to 60 seconds after propofol is injected. ECT may be given up to three times per week.
Study: NCT02458781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole 500mg given twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Ciprofloxacin 500mg given twice daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given twice daily for 14 days
Study: NCT01000233

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phytine (Phytate)
Study: NCT00783822

Intervention type: OTHER
Group type: OTHER
Intervention: RGCT
Description: rapid genetic counseling and testing
Study: NCT01833650

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: thymus honey mouthwash

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: thymus honey mouthwash

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: thymus honey mouthwash
Study: NCT05049915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bioglass (S53P4)
Description: surgical procedure: Masquelet defect augmentation with bioglass

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIA and TCP
Description: surgical procedure: Masquelet defect augmentation with RIA and TCP
Study: NCT00741624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bandage
Description: one application for one week
Study: NCT03896334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Isometric Handgrip Training
Description: The participants randomized to the experimental group will perform 24 weeks of isometric handgrip exercise training, three times/week for 16 minutes with time to rest.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham comparator - stretching and relaxation exercises
Description: The participants randomized to the control group (active comparator) will perform 24 weeks of stretching and relaxation exercise training, three times/week for 16 minutes with time to rest.
Study: NCT00624676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% benzoyl peroxide gel
Description: Once a day
Study: NCT03175328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous renal replacement therapies
Description: The choice of the method of continuous renal replacement therapy (device setting and anticoagulation method) is left to the discretion of each study site and was prescribed and monitored according to national guidelines.
Study: NCT01313052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forensic Assertive Community Treatment (FACT)
Description: Individuals in this arm will receive the services of an Assertive Community Treatment team and close supervision of a judge trained in the FACT model.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: Individuals in this arm of the study will receive an expedited appointment at a clinic specializing in the treatment of psychotic disorders. These individuals will receive the services of a therapist, psychiatrist, and case manager.
Study: NCT04600115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: 0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O-15 labeled radioactive water
Description: O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
Study: NCT04600115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day
Study: NCT02939508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colon originated: Neostigmin, Colonoscopy decompression, Surgery
Study: NCT03722589

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flublok
Description: 0.5 mL intramuscular dose of Flublok
Study: NCT02939508

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-colon originated: Neostigmin, Colonoscopy decompression
Study: NCT03722589

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flucelvax
Description: 0.5 mL intramuscular dose of Flucelvax

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix
Description: 0.5 mL intramuscular dose of Fluarix

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: 0.5 mL intramuscular dose of Fluzone

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone High-Dose
Description: 0.5 mL intramuscular dose of Fluzone
Study: NCT04415749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NasoShield
Description: NasoShield is an adenovirus-vectored anthrax vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NasoShield
Description: NasoShield is an adenovirus-vectored anthrax vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NasoShield
Description: NasoShield is an adenovirus-vectored anthrax vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline
Study: NCT01115153

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapy
Description: antibiotic treatment (5 days) therapy in patients with gangrenous appendicitis metronidazole 500 mg IV three times a day + amikacin 1 gr IV per day
Study: NCT03466645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: The 1st group receives vancomycin an hour before craniotomy
Study: NCT04415749

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT01867996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retosiban
Description: Retosiban will be supplied as clear colorless solution for infusion (300 mg in 20 mL via). Subject will receive loading dose of 6 mg over 5 min infusion followed by 6 mg/hour infusion for 12 hrs on Day 1 and Day 18.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFZ 600 mg
Description: EZF 600 mg will be supplied as a yellow, capsular-shaped, film-coated tablet. Subjects will receive EFZ 600mg OD in the evening from Day 3 till Day 18.
Study: NCT01191190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab/HDMP
Description: High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered based on specific schedule.~Each patient will receive a maximum of 3 cycles (one cycle is 28 days)
Study: NCT00002528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: 20 mg daily beginning within 6 weeks of surgery for 5 years or until relapse, whichever occurs first.
Study: NCT01828346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: Dose escalation part: (Drug escalation dose levels)~* Dose Level (1) - 13mg/m2 (twice a week for 3 of 4 weeks)~* Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks)~* Dose Level (2) - 13mg/m2 (twice weekly x 4 weeks)~* Dose Level (3a) - 17mg/m2 (twice weekly × 4 weeks)OR~* Dose Level (3b) - 17mg/m2 (twice a week for 3 of 4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacitidine
Description: Dose Level (0) - 75mg/m2 daily
Study: NCT01645449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium Tablets, 80 mg
Description: Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
Study: NCT03864315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HGM
Description: To Study the Efficacy of Therapeutic Pulsed Ultrasound in the Treatment of Vitiligo: a Randomized, Intra-individual, Left-right Comparison Study
Study: NCT01625455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally for a total of 7 days.
Study: NCT01645449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium Tablets, 80 mg
Description: Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
Study: NCT00002528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: 20 mg daily beginning within 6 weeks of surgery for 5 years or until relapse, whichever occurs first.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Either total mastectomy or, optionally if the tumor was smaller than 5 cm, a breast conserving procedure (lumpectomy or quadrantectomy).
Study: NCT02515604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Study: NCT00002528

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Either total mastectomy or, optionally if the tumor was smaller than 5 cm, a breast conserving procedure (lumpectomy or quadrantectomy).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: No radiotherapy is to be given after mastectomy. Radiotherapy is optional after breast conserving surgery according to prospectively determined guidelines within each institution. It should be given to the breast only and not to the draining node areas.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: No radiotherapy is to be given after mastectomy. Radiotherapy is optional after breast conserving surgery according to prospectively determined guidelines within each institution. It should be given to the breast only and not to the draining node areas.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary clearance
Description: Axillary node dissection.
Study: NCT05197543

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomechanical rupture risk assessment
Description: 3D computational model is created from CT angiographic images available during standard AAA diagnostic process. Vascular wall stress is assessed based on the 3D model using Finite element method to identify highly stressed parts of AAA and results are compared to populational wall strength information (gathered from previous large histological study), thus rupture risk (stress/strength ratio) of each particular AAA is estimated. Other relevant factors such as gender, blood pressure, presence of intraluminal thrombus etc. are used during the calculation as well.
Study: NCT00493909

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal opioids and thoracic paravertebral analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal opioids and thoracic paravertebral analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural analgesia
Study: NCT03355001

Intervention type: DEVICE
Intervention: Monosyn® Quick
Description: * Mucosal sutures in the facial and oral~* Dermal sutures, particularly in pediatrics~* Episiotomy~* Circumcision

Intervention type: DEVICE
Intervention: Monosyn® Quick
Description: * Mucosal sutures in the facial and oral~* Dermal sutures, particularly in pediatrics~* Episiotomy~* Circumcision

Intervention type: DEVICE
Intervention: Monosyn® Quick
Description: * Mucosal sutures in the facial and oral~* Dermal sutures, particularly in pediatrics~* Episiotomy~* Circumcision
Study: NCT03140150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Follow-up by Carelink express
Description: Followed by the cardiologist exclusively using Carelink Express during the study period: a single visit 1 to 3 months after implantation, then followed by the cardiologist and interrogation of the stimulator by Carelink Express

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up according to the usual recommendations
Description: According to follow-up recommendations for pacemakers, a visit is planned every 6 months if the patient is dependent on the stimulator (either visits to M6, M12, M18 and M24) or annually if the patient is not dependent on the stimulator (visits to M12 and M24).
Study: NCT02590627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Artemether-lumefantrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: Dihydroartemisinin-piperaquine
Study: NCT01955005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My HealtheVet Training
Description: Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet Skills Training
Description: Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
Study: NCT03384121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin 150 mg, 300 mg capsules and 25 mg/mL oral suspension
Description: Starting Dose (V2): 5 mg/kg/day (max 600mg/day) orally for 2 months followed by a 2 month washout period V4: After washout period, only Non-responders will escalate dose to 10 mg/kg/day (max 600mg/day) orally for 2 months
Study: NCT04241497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Description: 1 supervised exercise session at the hospital; 3 weeks of supervised home-based exercise training (3x/week); 9 weeks of unsupervised home-based exercise training (3x/week)
Study: NCT02860715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
Study: NCT03266159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib tablets
Description: Trametinib film coated tablets will be available as 0.5 mg and 2 mg dose strengths. Trametinib 0.5 mg will be yellow colored, modified oval, biconvex, tablets with 'GS' debossed on one face and 'TFC' on the opposing face.~Trametinib 2 mg will be pink colored, round, biconvex tablets with 'GS' debossed on one face and 'HMJ' on the opposing face. Doses will be taken at least 1 hour before or at least 2 hours after a meal.
Study: NCT03416829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulatory voice biofeedback
Description: Subjects will be provided cues regarding their vocal behavior in daily life. The cues will either be: 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly... 25% feedback = a vibrotactile cue on a smartwatch every 4th time the patient voices incorrectly... Summary feedback = the patient's overall compliance (percentage of voiced time within desired limits) will be presented via a smartwatch every 2 minutes of voicing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulatory voice biofeedback
Description: Subjects will be provided cues regarding their vocal behavior in daily life. The cues will either be: 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly... 25% feedback = a vibrotactile cue on a smartwatch every 4th time the patient voices incorrectly... Summary feedback = the patient's overall compliance (percentage of voiced time within desired limits) will be presented via a smartwatch every 2 minutes of voicing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulatory voice biofeedback
Description: Subjects will be provided cues regarding their vocal behavior in daily life. The cues will either be: 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly... 25% feedback = a vibrotactile cue on a smartwatch every 4th time the patient voices incorrectly... Summary feedback = the patient's overall compliance (percentage of voiced time within desired limits) will be presented via a smartwatch every 2 minutes of voicing.
Study: NCT02267044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: The drug used for the interscalene blocks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: The drug used for the interscalene blocks
Study: NCT03266159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib tablets
Description: Trametinib film coated tablets will be available as 0.5 mg and 2 mg dose strengths. Trametinib 0.5 mg will be yellow colored, modified oval, biconvex, tablets with 'GS' debossed on one face and 'TFC' on the opposing face.~Trametinib 2 mg will be pink colored, round, biconvex tablets with 'GS' debossed on one face and 'HMJ' on the opposing face. Doses will be taken at least 1 hour before or at least 2 hours after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib tablets
Description: Trametinib film coated tablets will be available as 0.5 mg and 2 mg dose strengths. Trametinib 0.5 mg will be yellow colored, modified oval, biconvex, tablets with 'GS' debossed on one face and 'TFC' on the opposing face.~Trametinib 2 mg will be pink colored, round, biconvex tablets with 'GS' debossed on one face and 'HMJ' on the opposing face. Doses will be taken at least 1 hour before or at least 2 hours after a meal.
Study: NCT03466645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: The 2nd group receives cefazolin an hour before craniotomy
Study: NCT02913898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IBLT
Description: Information bias learning task-- a computer based task in which positive information is more useful when learning how best to complete it

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: IBLT control
Description: A control version of the IBLT task-- a computer based task in which both positive and negative information is useful when learning how to complete it